Selective TRK Inhibitor CH7057288 Against TRK Fusion-Driven Cancer

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-17-1180
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Discovery of GNF-5837, a Selective TRK Inhibitor With Efficacy in Rodent Cancer Tumor Models

ACS Medicinal Chemistry Letters
Organic ChemistryBiochemistryDrug Discovery
2012English

Combating Acquired TRK Inhibitor Resistance

Cancer Discovery
Oncology
2019English

Abstract P6-20-02: Activity of Larotrectinib, a Highly Selective Inhibitor of Tropomyosin Receptor Kinase, in TRK Fusion Breast Cancers

2019English

Opioid Kappa Receptor Selective Agonist TRK-820 (Nalfurafine Hydrochloride)

2012English

Methods for Identifying Patients With Tropomyosin Receptor Kinase (TRK) Fusion Cancer

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2019English

Tumor-Agnostic Therapy Gets on TRK

Science
MultidisciplinaryPhilosophy of ScienceHistory
2018English

TFG (TRK-fused Gene)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2011English

ETV6-NTRK3 Induces Aggressive Acute Lymphoblastic Leukemia Highly Sensitive to Selective TRK Inhibition

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

Larotrectinib OK'd for Cancers With TRK Fusions

Cancer Discovery
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy